Evaluating the Effect of Dexmedetomidine on Hemodynamic Status of Patients with Septic Shock Admitted to Intensive Care Unit: A Single-Blind Randomized Controlled Trial

Document Type : Other

Authors

1 Department of Pharmacotherapy, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran.

2 Department of Anesthesiology and Critical Care Medicine, Imam Khomeini Hospital, Mazandaran University of Medical Sciences, Sari, Iran.

3 Pharmaceutical Research Center, Department of Clinical Pharmacy, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran.

4 Department of Clinical pharmacy, Antimicrobial Resistance Research Center, Ghaemshahr Razi hospital, Mazandaran University of Medical Science,sari,Iran.

5 Director of Medical Education Development Center, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.

Abstract

Septic shock, known as the most severe complication of sepsis, is a serious medical condition that can lead to death. Clinical symptoms of sepsis include changes in body temperature in the form of hypothermia or hyperthermia, tachypnea or hyperventilation, tachycardia, leukocytosis or leukopenia, and variations in blood pressure, as well as altered state of consciousness. One of the main problems in septic shock is poor response along with reduced vascular reactivity to vasopressors used to increase blood pressure. In addition to being the state-of-the-art treatment including volume load and vasopressor, use of alpha-2 agonists e.g. dexmedetomidine (DXM) in septic shock can reduce vasopressors needed to restore adequate blood pressure. They can further moderate massive release of endogenous catecholamine. Therefore, the purpose of this study was to investigate the effect of DXM on outcomes of patients with septic shock, especially their needs for vasopressors and impacts on their hemodynamic status. This single-blind randomized controlled trial was performed on a total number of 66 patients with septic shock admitted to the intensive care unit (ICU) of Imam Khomeini Teaching Hospital in the city of Sari, in northern Iran. To this end, DXM (0.6 µg/kg/h) and normal saline (6ml/kg/h) were infused for 12 h in the study and control groups, respectively. The results revealed that DXM could increase mean arterial pressure (MAP) (p=0.021), systolic blood pressure (SBP) (p=0.002), and diastolic blood pressure (DBP) (p=0.32) accompanied by reduced heart rate (p

Graphical Abstract

Evaluating the Effect of Dexmedetomidine on Hemodynamic Status of Patients with Septic Shock Admitted to Intensive Care Unit: A Single-Blind Randomized Controlled Trial

Keywords


  1. Funk DJ, Parrillo JE, Kumar A. Sepsis and septic shock: a history. Critical care clinics. 2009;25(1):83-101.
  2. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. New England Journal of Medicine. 2001;345(19):1368-77.
  3. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). Jama. 2016;315(8):801-10.
  4. Annane D, Trabold F, Sharshar T, Jarrin I, Blanc AS, Raphael JC, et al. Inappropriate sympathetic activation at onset of septic shock: a spectral analysis approach. American journal of respiratory and critical care medicine. 1999;160(2):458-65.
  5. Friedman G, Silva E, Vincent J-L. Has the mortality of septic shock changed with time? Critical care medicine. 1998;26(12):2078-86.
  6. Kortesuo P, Ahola M, Kangas M, Leino T, Laakso S, Vuorilehto L, et al. Alkyl-substituted silica gel as a carrier in the controlled release of DEXMEDETOMIDINE. Journal of controlled release. 2001;76(3):227-38.
  7. Pichot C, Géloën A, Ghignone M, Quintin L. Alpha-2 agonists to reduce vasopressor requirements in septic shock? Medical hypotheses. 2010;75(6):652-6.
  8. Geloen A, Chapelier K, Cividjian A, Dantony E, Rabilloud M, May C, et al. Clonidine and DEXMEDETOMIDINE increase the pressor response to norepinephrine in experimental sepsis: a pilot study. Critical care medicine. 2013;41(12):e431-e8.
  9. Bhana N, Goa KL, McClellan KJ. DEXMEDETOMIDINE. Drugs. 2000;59(2):263-8.
  10. De Wolf AM, Fragen RJ, Avram MJ, Fitzgerald PC, Rahimi-Danesh F. The pharmacokinetics of DEXMEDETOMIDINE in volunteers with severe renal impairment. Anesthesia & Analgesia. 2001;93(5):1205-9.
  11. Karol MD, Maze M. Pharmacokinetics and interaction pharmacodynamics of DEXMEDETOMIDINE in humans. Best Practice & Research Clinical Anaesthesiology. 2000;14(2):261-9.
  12. Miranda ML, Balarini MM, Bouskela E. DEXMEDETOMIDINE attenuates the microcirculatory derangements evoked by experimental sepsis. Anesthesiology: The Journal of the American Society of Anesthesiologists. 2015;122(3):619-30.
  13. Yu T, Pan C, Liu S, Guo F, Longhini F, Yang Y, et al. Different effects of propofol and DEXMEDETOMIDINE on preload dependency in endotoxemic shock with norepinephrine infusion: a randomized case-control study. Critical Care. 2014;18(1):P417.
  14. Penttilä J, Helminen A, Anttila M, Hinkka S, Scheinin H. Cardiovascular and parasympathetic effects of DEXMEDETOMIDINE in healthy subjects. Canadian journal of physiology and pharmacology. 2004;82(5):359-62.
  15. Leroy S, Aladin L, Laplace C, Jalem S, Rosenthal J-M, Abrial A, et al. Introduction of a centrally anti-hypertensive, clonidine, reduces noradrenaline requirements in septic shock caused by necrotizing enterocolitis. The American journal of emergency medicine. 2017;35(2):377. e3-. e5.
  16. Dyck J, Maze M, Haack C, Vuorilehto L, Shafer S. The pharmacokinetics and hemodynamic effects of intravenous and intramuscular DEXMEDETOMIDINE hydrochloride in adult human volunteers. Anesthesiology. 1993;78(5):813-20.
  17. Lin T-F, Yeh Y-C, Lin F-S, Wang Y-P, Lin C-J, Sun W-Z, et al. Effect of combining DEXMEDETOMIDINE and morphine for intravenous patient-controlled analgesia. British journal of anaesthesia. 2008;102(1):117-22.